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Abstract: SHIP2 is a phosphatase that acts at the 5-position of 
phosphatidylinositol 3,4,5-trisphosphate. It is one of several 
enzymes that catalyse dephosphorylation at the 5-position of 
phosphoinositides or inositol phosphates. SHIP2 has a confirmed 
role in opsismodysplasia, a disease of bone development, but 
also interacts with proteins involved in insulin signalling, 
cytoskeletal function (thus having an impact on endocytosis, 
adhesion, proliferation and apoptosis) and immune system 
function. The structure of three domains (constituting about 38% 
of the protein) is known. Inhibitors of SHIP2 activity have been 
designed to interact with the catalytic domain with sub-micromolar 
IC50 values: these come from a range of structural classes and 
have been shown to have in vivo effects consistent with SHIP2 
inhibition. Much remains unknown about the roles of SHIP2 and 
possible future directions for research are indicated. 
1. Introduction 
SHIP2 is an enzyme that catalyses dephosphorylation at the 5-
position of mainly phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3) to generate phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4)P2; Figure 1). In catalysing this reaction, 
SHIP2 is one of several human enzymes that can 
dephosphorylate at the 5-position of phosphoinositides or inositol 
phosphates (Table 1). The inositol polyphosphate 5-
phosphatases have been the subject of several general reviews 
[1]. 
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trisphosphate 5-phosphatase 2 
(SHIP2) 
O15357 INPPL1 1258 
Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 1 
(SHIP1) 
Q92835 INPP5D 1189 
Phosphatidylinositol 4,5-
bisphosphate 5-phosphatase A 
Q15735 INPP5J 1006 
Inositol polyphosphate 5-
phosphatase OCRL-1 
Q01968 OCRL 901 
Type II inositol 1,4,5-
trisphosphate 5-phosphatase 
P32019 INPP5B 993 
72 kDa inositol polyphosphate 5-
phosphatase 
Q9NRR6 INPP5E 644 
Inositol polyphosphate 5-
phosphatase K (SKIP) 
Q9BT40 INPP5K 448 
Synaptojanin-1 O43426 SYNJ1 1573 
Synaptojanin-2 O15056 SYNJ2 1496 
Type I inositol 1,4,5-
trisphosphate 5-phosphatase 
Q14642 INPP5A 412 
 
 
Phosphoinositides generally [1a], and PtdIns(3,4,5)P3 more 
specifically [3], have been the subject of recent reviews: these 
papers should be referred to for details of the roles of 
PtdIns(3,4,5)P3 in the brief summary that follows. PtdIns(3,4,5)P3 
is found embedded in membranes with the phosphorylated 
inositol headgroup exposed to the cytoplasm. It is predominantly 
synthesized from phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4,5)P2) in a reaction catalysed by phosphatidylinositol 3-
kinase (PI3K) in response to extracellular stimuli. PtdIns(3,4,5)P3 
functions as a second messenger, amplifying an external stimulus 
to generate (or not) a response. Effector proteins are recruited 
from the cytoplasm and bind to the inositol trisphosphate 
headgroup moiety through their PH domain, resulting in activation 
of the protein and/or the membrane translocation of the protein. 
Among the processes controlled or influenced by PtdIns(3,4,5)P3 
are cellular growth, proliferation, apoptosis, cytoskeletal 
rearrangement, chemotaxis and neuronal development and 
function. Perturbations in PtdIns(3,4,5)P3 signalling have been 
linked to roles in cancer, inflammation, cardiovascular disease 
and diabetes. By dephosphorylating PtdIns(3,4,5)P3 at the 5-
position SHIP2 potentially has an influence on all these processes. 
It should be noted that dephosphorylation of PtdIns(3,4,5)P3 at the 
3-position by the tumour suppressor PTEN (UniProtKB ID 
P60484) to generate phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4,5)P2) is also important [4]. The contrasting roles of 
SHIP2 and PTEN have been studied [5]. 
 
Scheme 1. The reaction catalysed by SHIP2. The site of reaction is identified 
by the dotted ellipse on the lower right. The exact nature of the fatty acids in the 
structure is variable [2]. 
Aside from cleaving the 5-phosphate from PtdIns(3,4,5)P3 SHIP2, 
or truncated versions of it, have also been reported to catalyse 
the in vitro and in vivo removal of the 5-phosphate from 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) [6], and the 
in vitro removal of the 5-phosphate from inositol 1,3,4,5-
tetrakisphosphate (Ins(1,3,4,5)P4) [7], and Ins(1,4,5,6)P4, 
Ins(2,4,5,6)P4, Ins(1,2,3,4,5)P5 and diC4PtdIns(3,5)P2 [8]. Whether 
these reactions occur in vivo (or even whether some of these 
substrates clearly exist in vivo) is unknown. Similarities and 
differences between the reaction specificity of SHIP1 and SHIP2 
are discussed elsewhere [1a]. 
 
However, the role of SHIP2 is not limited to its catalytic activity. 
As discussed below, SHIP2 is able to interact with many proteins 
through four different interaction motifs and these interactions 
influence a number of processes including insulin signalling (and, 
thus, diabetes and metabolic syndrome), cytoskeletal 
organisation and function (thus influencing endocytosis, adhesion 






and proliferation), and immune system function. Despite indirect 
evidence for SHIP2 involvement in these processes based on 
essentially in vitro models, genetic evidence has provided a role 
for SHIP2 only in human bone maturation: indeed, rare mutations 
in INPPL1 cause opsismodysplasia, a disease of bone maturation 
[9]. 
 
This paper starts by discussing the sequence and structure of 
SHIP2. It then goes on to review the role of SHIP2 in bone 
maturation, insulin signalling, cytoskeletal organisation and 
function, and immune system function at least partly through a 
discussion of the proteins with which it interacts. It concludes by 
reviewing the development of modulators of SHIP2 activity, 
discussing both their in vitro and in vivo effects. 
 
2. SHIP2 Sequence and Structure 
SHIP2 (UniProtKB ID O15357) is the product of the INPPL1 gene 
on human chromosome 11 [10]. An earlier paper had partially 
identified the sequence, but sequencing mistakes resulted in 
errors in both the N- and C-termini [11]. Although commonly (and 
conveniently) called SHIP2 the official name of the enzyme is 
phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 (EC 
3.1.3.86). Two isoforms of the protein, generated by alternative 
splicing, are known to exist. The longer isoform 1 has 1,258 
residues (Figure 2) with the shorter isoform 2 having 1,016 
residues, missing residues 1-242 of isoform 1. There are several 
natural variants that are mutated from the human sequence 
shown in Figure 2. The R401W, P659S, W688C and F722I 
variants have all been associated with the genetic disease 
opsismodysplasia (suggesting a key role in endochondral 
ossification [9]), and the L632I and N982S variants have been 
associated with susceptibility to non-insulin dependent diabetes 
mellitus [12]. The T180A mutation has been found in families 
suffering from lymphatic dysfunction [13]. Other natural variants are 







Figure 1. The amino acid sequence of human SHIP2. (UniProtKB ID O15357). 
The first 242 residues (shown in ITALICS) are missing from isoform 2. Residues 
21-117 (shown in BOLD ITALICS) form an SH2 domain. Residues 139-143 and 
residues 944-949, constituting SH3-binding motifs, and residues 983-986, 
forming an NPXY motif, are shown in UNDERLINED BOLD. The sterile alpha 
motif, residues 1196-1258, is shown UNDERLINED. 
Residue T165 is reported to be a site of phosphorylation [15], as 
are residues S132, T1254 and S1258 [16], S241 [15][17], T958 [18], 
Y986 [19], Y1135 [17][20] and Y1162 [21]. (Further putative 
phosphorylation sites can be found listed on the PhosphoSitePlus 
web site: it may be that most of these putative sites have been 
observed only at very low stoichiometries, and they have often not 
been confirmed by the use of phospho-specific antibodies.) The 
reversible phosphorylation of SHIP2 may have an important role 
to play in the interactions SHIP2 makes with other proteins, in 






phosphoinositide signalling, and catalytic activity [22]. Residue 
K315 is reported to be a site of ubiquitination in EGF-stimulated 
COS-7 cells [23]. 
 
Residues 21-117 form an SH2 domain (missing from isoform 2). 
Residues 139-142 (sequence PPLP) and 140-143 (sequence 
PLPP) are both PxxP motifs that can bind SH3 domains. 
Residues 944-949 (sequence PPAPPR) constitute another SH3-
binding motif and residues 983-986 (sequence NPAY) form an 
NPXY motif: both these motifs lie within a region of compositional 
bias (residues 935-1105) that has a proline residue at 53 out of 
171 positions. Residues 1196-1258 form a SAM (sterile alpha 
motif) domain. The significance of these domains and motifs is 
that they can interact with other proteins. SH2 domains bind to 
phosphotyrosine-containing peptides 3-6 residues C-terminal to 
the phosphorylated tyrosine [24]: a novel hydrophobic N-terminal 
motif for SHIP2 binding through its SH2 domain has been 
identified [25]. The PPAPPR motif is a ligand for SH3 domains of 
proteins [26]. The NPXY motif is a sequence highly favoured for 
forming β-turns [27] and is commonly found as the ligand or 
substrate for phosphotyrosine binding (PTB) domains, though the 
tyrosine in the motif does not necessarily need to be 
phosphorylated to be recognised by the PTB domains [28]: the 
tyrosine in the SHIP2 NPXY motif, Y986, is a known 
phosphorylation site [19]. SAM domains are known to interact with 
a wide range of proteins and nucleic acids [29]. A variety of 
methods, but principally immunoprecipitation followed by mass 
spectrometry, have been used to identify proteins that, under the 
conditions of the experiment, can interact with SHIP2 [6c][19a][30] but 
whether or not they do so in vivo at physiological levels of the 
proteins has not always been definitively or firmly established. 
Some of these possible interactions have been discussed 
previously [1d][22]. 
 
Alignment of the human SHIP2 sequence with those from other 
species (Supplementary Information, Figure S1) shows a high 
degree of identity with the mouse (Mus musculus; 96% sequence 
identity [31]) and rat (Rattus norvegicus; 96% [32]) sequences and 
a lower degree of identity with two sequences from zebrafish 
(Danio rerio; 69% and 43%). The SHIP2 sequence is also similar 
to that of SHIP1, having approximately 42% sequence identity 
(Supplementary Information, Figure S2). In SHIP1 residues 725-
863 have been identified as a C2 domain [33], though how the 
identification was made is not clear: the cited reference [34] 
describes the sequence of SHIP1 but does not identify a C2 
domain. Residues 742-884 of SHIP2 share a similar sequence to 
the putative C2 domain of SHIP1 so may also be a C2 domain. 
C2 domains are highly variable in sequence, have an eight-
stranded anti-parallel β-sandwich structure (formed in two 
different ways), and are involved in binding calcium or lipids [35]. 
The definitive identification of a C2 domain in SHIP2 will have to 
wait until the structure is solved: a preliminary report has 
described the crystallization, but not the structure, of this domain 
[36]. 
 
There are two NMR structures of the SAM domain (Figure 3). The 
2K4P structure [37] has residues 1194-1258 (65 residues), and the 
2KSO structure [38] has residues 1200-1258 (59 residues) in 
complex with the SAM domain (residues 14-72, 59 residues) of 
the ephrin-A2 receptor (a tyrosine kinase, UniProtKB ID P29317). 
The SAM domain is formed of five α-helices forming a 4-5 helical 
bundle with two orthogonally packed alpha-hairpins. Modelling 
studies suggest that the SAM domain of ARAP3 (UniProtKB ID 
Q05CH1) interacts with SHIP2 in the same way as the ephrin A2 
receptor [39]. This domain is capable of homo- and hetero-
dimerization on two faces, meaning that proteins containing SAM 
domains can potentially form oligomers [29]. 
 
There are also two crystal structures of the ligand binding domain 
both with residues 419-732 (314 residues). The 3NR8 structure 
[40] is the apo-enzyme at 2.8Å resolution and the 4A9C structure 
(Figure 4) [41] is at 2.1Å resolution and contains a synthetic ligand, 
biphenyl 2,3',4,5',6-pentakisphosphate (Figure 5), in the substrate 
binding site as a headgroup surrogate. (This ligand and the 
interactions it makes with the protein are discussed further in the 
section below on SHIP2 modulators.) The structure of the binding 
site domain is based on a core of two stacked β-sheets, one with 
five strands and the other with seven strands. Around this core 
are a number of α-helices, a couple of short β-sheets and several 
flexible loops. Despite the absence of the ligand the 3NR8 
structure is very similar to the 4A9C structure with just a couple of 
side chains and a few water molecules in and around the ligand 
binding site in different positions. Crystals of residues 420-878 
have been obtained but the structure has yet to be solved [36]. 
 
  
Figure 2. The SAM domain of SHIP2. The overall structure is shown by the 
cartoon coloured blue at the N-terminus through green, yellow and orange to 
red at the C-terminus. Taken from the 2K4P structure [37]. 







Figure 3. The structure of the ligand binding domain of SHIP2. The structure is 
shown by the cartoon coloured blue at the N-terminus through green, yellow 
and orange to red at the C-terminus. The ligand, biphenyl 2,3',4,5',6-
pentakisphosphate with cyan carbon atoms, is visible on the right. Taken from 
the 4A9C structure [41]. 
 
 
Figure 4. The residues around the ligand in the 4A9C crystal structure of 
SHIP2. The ligand, biphenyl 2,3',4,5',6-pentakisphosphate, is coloured with 
cyan carbon atoms. The red spheres are the oxygen atoms of water molecules. 
Finally, there is an NMR structure of the SH2 domain, residues 
20-117, 2MK2 (Northeast Structural Genomics Consortium, 
unpublished; Figure 6). This has two helices sandwiching a three-
stranded antiparallel β-sheet. This is a typical SH2 domain 
structure with the residues commonly involved in the binding of 
phosphotyrosine-containing peptides conserved (Arg27 in α-helix 
A, Arg47 in β-sheet B, Ser49 and Glu50 in the loop between β-
sheet B and β-sheet C, Val60 in β-sheet C, and His67 in β-sheet 
D). In SH2 domains the phosphotyrosine-containing peptide 
usually (but not always) binds with the residues’ C-terminal to the 
phosphotyrosine lying perpendicular to and across the core β-





Figure 5. The SH2 domain of SHIP2. The overall structure is shown by the 
cartoon coloured blue at the N-terminus through green, yellow and orange to 
red at the C-terminus. Some of the α-helices (aA) and β-sheets (bB, bC and bD) 
are identified as are the residues (shown as sticks and labelled) that are 
involved in binding the phosphotyrosine-containing peptide. Taken from the 
2MK2 structure (Northeast Structural Genomics Consortium, unpublished). 
3. SHIP2 in Opsismodysplasia 
The established role of SHIP2 in human disease or pathology is 
in opsismodysplasia [43]. Opsismodysplasia is a congenital 
autosomal recessive disease [44] that is characterized by a delay 
in ossification, the maturation process whereby cartilage is 
replaced by bone. Whole genome sequencing of three members 
of the same family suffering from opsismodysplasia revealed 
mutations in the INPPL1 gene, with analysis of a further twelve 
families suggesting that INPPL1 mutations account for 60% of 
cases of opsismodysplasia [45]. Frameshift, deletion and missense 
mutations in the INPPL1 gene have been shown to be responsible 
for some, but not all, cases of opsismodysplasia [9][45][46]. SHIP1 
has also been shown to play a role in bone development [47]. 






4. SHIP2 in Insulin Signalling 
Early work on SHIP2 ascribed to it roles in insulin signalling and 
diabetes [48]. However, insulin signalling is no longer regarded as 
being the main pathway where SHIP2 is involved [49]. Despite this, 
research into a possible role of SHIP2 in insulin signalling and 
diabetes continues because some genetic studies suggest SHIP2 
does have a role to play. 
 
An argument that SHIP2 is involved in insulin signalling came 
from the finding that mutations in the SHIP2 gene, INPPL1, 
contribute to the genetic susceptibility of rats and humans to type 
2 diabetes [12][50] and other symptoms of metabolic syndrome [51]. 
In a dietary rat model of metabolic syndrome antisense 
oligonucleotides against SHIP2 improve the muscle insulin 
sensitivity [52]. In men with type 1 diabetes mutation of the INPPL1 
gene may contribute to susceptibility to metabolic syndrome [53]. 
Small molecule inhibitors of SHIP1 have been shown to reverse 
diet-associated obesity and metabolic syndrome in mice, though 
the possible inhibition of SHIP2 cannot be excluded [54]. The 
absence of SHIP2 in mice also confers resistance to dietary 
obesity [55]. 
 
In the mouse brain insulin has neuroprotective effects that are 
reduced when SHIP2 is overexpressed [56]. Mice overexpressing 
SHIP2 exhibited impaired performance in tests of memory, 
avoidance and recognition. Diabetic mice had higher levels of 
SHIP2 in the brain than non-diabetic mice, and the impairment of 
brain function in the diabetic mice was reduced in mice expressing 
catalytically dead SHIP2. Metabolic syndrome, of which type 2 
diabetes is a component, is a risk factor for Alzheimer’s disease 
(AD) and single nucleotide polymorphisms in the INPPL1 gene 
have suggested a possible association between SHIP2 activity 
and AD [57]: the possible role of SHIP2 in AD is discussed further 
below. 
 
Mice expressing a germline catalytically inactive SHIP2 mutant 
protein are viable, but have defects in the development of muscle, 
adipose tissue and the female genital tract, and in somatic growth 
[49]. Glucose tolerance, insulin sensitivity and insulin-induced 
Akt/PKB phosphorylation were unaffected, but lipid metabolism 
and insulin secretion were. Variants of these mice expressing also 
a catalytically inactive PI3K might be expected to have a 
phenotype where the two mutations cancel each other out, but 
this was not the case, possibly suggesting that some of the effects 
of an inactive SHIP2 may be due to a lack of PtdIns(3,4)P2 [49]. 
5. SHIP2 and the Cytoskeleton: Endocytosis, 
Adhesion, Proliferation and Apoptosis 
In some cell types the downregulation of INPPL1 expression or 
the inhibition of SHIP2 activity has been shown to induce 
apoptosis. Virusecurinine, a plant alkaloid, downregulates 
INPPL1 expression (thus reducing the amount of SHIP2) in K562 
cells and induces apoptosis [58]. SHIP2-expressing multiple 
myeloma breast cancer cells lacking SHIP1 expression, when 
treated with pan-SHIP1/2 inhibitors, undergo apoptosis [59]. 
Palmitate induces apoptosis in HepG2 cells which was increased 
when wild-type SHIP2 was overexpressed and decreased if 
SHIP2 was inhibited [60]. However, contrarily, in other cell types 
the overexpression of INPPL1 expression has been shown to 
increase apoptosis. Thus, in gastric cancer where INPPL1 
expression is usually downregulated the overexpression of 
INPPL1 induced apoptosis (as well as inhibiting cell proliferation 
and suppressing cell motility and invasion) [61].  
 
In colorectal cancer samples SHIP2 is overexpressed and has an 
increased level of activity [62]. Inhibition of SHIP2 reduced cell 
viability, and both SHIP2 inhibition and knockdown reduced the 
amount of phosphorylated PKB resulting in sensitivity to 
chemotherapeutics. SHIP2 knockdown also reduced cell 
migration and invasive capacity but had no effect on cell adhesion. 
 
SHIP2 plays an important role in cell adhesion and spreading. It 
could do so at least in part through an interaction with the p130Cas 
adaptor protein (UniProtKB ID P56945), also known as the breast 
cancer anti-estrogen resistance protein 1, that is a mediator of 
actin cytoskeleton organization and associates with 
phosphorylated SHIP2 through the SHIP2 SH2 domain [30g]. HeLa 
cells expressing SHIP2 exhibited increased adhesion that was not 
observed when the R47G SH2 domain SHIP2 mutant was 
expressed: cells with mutant SHIP2 adhered between a third and 
a half of the time of those cells expressing the wild-type protein, 
and the mutant cells spread more slowly than wild-type cells [30g]. 
Catalytically dead SHIP2 also inhibited cell spreading [30g]. These 
roles of SHIP2 are dependent on the phosphorylation status: the 
phosphorylations are catalysed by Src kinases [19b]. If Src is 
inhibited then phosphorylation of SHIP2 tyrosine residues falls [63]. 
HeLa cells with SHIP2 expression suppressed by RNA 
interference (RNAi) had defects in cell spreading associated with 
disruption of cytoskeletal proteins [64]. 
 
Vinexin (UniProtKB ID O60504) is a cytoskeletal protein involved 
in cell spreading and cytoskeletal organization [65]. The C-terminus 
of SHIP2 interacts with vinexin: the interaction has no effect on 
SHIP2 catalytic activity [30l]. The interaction between SHIP2 and 
vinexin promotes localization of SHIP2 at the cell periphery and 
increases cellular adhesion. 
 
Intersectins are scaffold proteins that have roles to play in signal 
transduction, cytoskeletal rearrangements and cytosis [66]. In 
response to EGF, SHIP2 associates with intersectin-1 (UniProtKB 
ID Q15811) and may recruit it to the plasma membrane of COS-
7 cells [30n]: the interaction occurs through the SHIP2 proline-rich 
region. In COS-7 cells the interaction with intersectin 
concentrates SHIP2 at endocytic clathrin-coated pits (CCPs) 
early in pit formation, though dissociation occurs before fission [6b]. 
CCP lifetime is shortened by reducing the expression of SHIP2 or 
increasing production of PtdIns(3,4,5)P3 and/or PtdIns(4,5)P2, 
both of which result in an increase in the rate of CCP maturation, 
though it was unclear which of these scenarios had this effect. 
More recent work has suggested that in N1 glioblastoma cells a 
fall in the amount of PtdIns(3,4,5)P3 controls proliferation and a 






fall in the amount of PtdIns(4,5)P2 controls migration [6c]. SHIP2 is 
also involved in a clathrin-independent endocytic pathway that 
utilises endophilin A (UniProtKB IDs Q99962, Q99961 and 
Q99963) and is involved in the ligand-stimulated uptake of several 
G-protein-coupled receptors [67]. 
 
There are three types of filamin in human cells, filamins A, B and 
C (UniProtKB IDs P21333, O75369 and Q14315, respectively). 
These proteins are involved in the organization of the actin 
cytoskeleton, contributing to the mechanical stability of the 
plasma membrane and the cell cortex, and also have roles in cell 
migration and adhesion [68]. In fulfilling these roles they have been 
shown to interact with more than ninety other proteins, one of 
which is SHIP2 [30f][69]. Filamin and SHIP2 co-localize at Z-lines 
and the sarcolemma in striated muscle and at membrane ruffles 
in COS-7 cells. (Membrane ruffling is the formation of a motile cell 
surface that contains a network of freshly polymerised actin 
filaments.) Levels of PtdIns(3,4,5)P3 and the presence of sub-
membranous actin at membrane ruffles were dependent on 
SHIP2 catalytic activity [30f]. The regulation of cortical and sub-
membranous actin by the localised hydrolysis of PtdIns(3,4,5)P3 
may be orchestrated by a complex between SHIP2, filamin, actin 
and the platelet receptor for the von Willebrand factor glycoprotein 
1b-IX-V (GPIb-IX-V) [69].  
 
The formation of lamellipodia can be dependent on 
PtdIns(3,4,5)P3. The sub-cellular location of LL5β (PHLDB2; 
UniProtKB ID Q86SQ0) is dictated by PtdIns(3,4,5)P3: it interacts 
with the actin cross-linking filamin A at the PtdIns(3,4,5)P3-
enriched leading edge of lamellipodia. Filamin A co-localizes with 
SHIP2 which dephosphorylates PtdIns(3,4,5)P3 at the same 
location [70]. Lamellipodia formation is associated with a protein 
complex that includes SHIP2, lamellipodin (UniProtKB ID 
Q70E73) and filamin: the assembling of this complex is regulated 
by nephrin (UniProtKB ID O60500) [71]. SHIP2 is also important 
for PtdIns(3,4)P2 production which is a specific ligand of 
lamellipodin [72]. 
 
SHIP2 binds directly to the HGF receptor, c-met (UniProtKB ID 
P08581) [30k]. HGF stimulates cell spreading and scattering, but 
this is suppressed if a catalytically inactive mutant of SHIP2 is 
present in the cell. 
 
SHIP2 binds to actin tails that form beneath enveloped poxviruses 
following their fusion with the plasma membrane [73]. The binding 
requires phosphotyrosine, neural Wiskott-Aldrich syndrome 
protein (N-WASP; UniProtKB ID O00401) and tyrosine kinases 
from the Abl and Src families. Cells lacking SHIP2 have normal 
actin tails but release more virus particles. N-WASP also plays a 
role in the formation of invadopodia which are actin-rich 
protrusions from cell membranes that extend into the extracellular 
matrix, and which may play a role in some cancers. Invadopodia 
formation is associated with increased activity of PI3K and SHIP2 
and the consequent increased levels of PtdIns(3,4)P2 [74]. SHIP2 
regulates invadopodium maturation, but not initiation, by 
associating (along with Tks5 (UniProtKB ID Q5TCZ1)) with an 
invadopodium initiating complex consisting of N-WASP, cortactin 
(UniProtKB ID Q14247), cofilin (UniProtKB ID P23528, Q9Y281) 
and actin [75]. 
 
In U251 glioma cells a GTP-dependent interaction between RhoA 
(UniProtKB ID P61586) and SHIP2 is associated with spreading 
and migration [76]. RhoA exhibits polarization in migrating cells: 
this polarization and migration are attenuated in cells expressing 
SHIP2 mutants defective in RhoA binding. SHIP2-depleted cells 
have improper PtdIns(3,4,5)P3 localization which is not restored 
by a SHIP2 mutant defective in RhoA binding. In MDCK cells 
expressing the hepatitis C virus core protein, apicobasal polarity 
is disrupted, this being associated with decreased expression of 
SHIP2 and the polarity protein Dlg1 (UniProtKB ID Q12959) and 
decreased activity of RhoA [77]. Increasing the expression of 
SHIP2 restored cell polarity and RhoA activity. ARAP3 
(UniProtKB ID Q8WWN8) is a PtdIns(3,4,5)P3-dependent 
GTPase-activating protein that regulates Arf and Rho proteins 
thus modulating actin cytoskeleton remodelling. ARAP3 and 
SHIP2 bind to each other in a heterodimeric interaction between 
their SAM domains [78]. 
 
The proliferation rate of K562 erythroleukemia cells is reduced by 
overexpression of SHIP2 with cells accumulating in the G2/M 
phase of the cell cycle [79]. The decrease in proliferation rate is 
accompanied by an increase in the amount of PtdIns(3,4)P2. 
 
Neuritogenesis following stimulation with nerve growth factor 
(NGF) is preceded by an accumulation of PtdIns(3,4,5)P3 and a 
consequent activation of Rac1/Cdc42. In SHIP2-deficient PC12 
cells NGF-induced Rac1/Cdc42 activation and PtdIns(3,4,5)P3 
accumulation are increased with a consequent increase in the 
number and length of neurites [80]. 
 
In 3T3-L1 preadipocytes platelet-derived growth factor (PDGF) 
stimulates proliferation and SHIP2 tyrosine phosphorylation. One 
of the pathways that regulates proliferation involves PI3K, 
PtdIns(3,4,5)P3 and Akt, and another involves Shc, Ras and Erk 
1/2. PDGF stimulates SHIP2 tyrosine phosphorylation and 
association with Shc [18]. By failing to dephosphorylate 
PtdIns(3,4,5)P3 catalytically inactive SHIP2 attenuates PDGF 
signalling and inhibits proliferation [81]. The presence of inactive 
SHIP2 resulted in greater ubiquitination, and subsequent 
lysosomal degradation, of the PDGF receptor. 
 
In multiple clinical samples of laryngeal squamous cell carcinoma 
(LSCC) elevated levels of SHIP2 have been detected [82]. SHIP2 
expression correlated with clinical stage, metastasis, recurrence, 
and poor survival. Similarly, elevated SHIP2 expression is 
associated with poor prognosis in non-small cell lung cancer [83] 
and in hepatocellular carcinoma [84]. These results suggest that 
SHIP2 plays an important role in cancer development and 
progression, and may be useful in diagnostics and as a 
therapeutic target. In colorectal cancer cells the expression of 
SHIP2 is significantly higher than in equivalent non-cancerous 
cells and is correlated with metastasis and overall survival [85]. 
 






In oestrogen receptor-negative breast cancer stem cells (BCSCs) 
SHIP2 is expressed at higher levels than in non-BCSCs: the 
higher expression is associated with increased expression of 
JNK1 (UniProtKB ID P45983), JNK2 (UniProtKB ID P45984) and 
vimentin (UniProtKB ID P08670), and increased tumourogenicity 
[86]. 
 
Treatment of HeLa cells and of MDA-MB-231 breast cancer cells 
(both with RNAi suppression of SHIP2 expression) with EGF led 
to increased EGF receptor (EGFR) internalization and 
degradation consequent upon increased association of EGFR 
with c-Cbl ubiquitin ligase and EGFR ubiquitination [87]. In these 
cells the EGF-stimulated activation of Akt was reduced, and the 
cytokine receptor CXCR4 (UniProtKB ID P61073) is down-
regulated [88]: CXCR4 is on the EGF-Akt pathway and plays an 
important role in metastasis. SHIP2 can be ubiquitinated on K315 
but the ubiquitination is catalysed by neither c-Cbl nor Nedd4-1: 
ubiquitination increases within thirty minutes of stimulation with 
EGF, correlating with a loss of interaction between the SHIP2 SH2 
domain and c-Cbl, suggesting that the association of c-Cbl with 
SHIP2 masks the ubiquitination site [23]. The PR130 regulatory 
subunit of protein phosphatase 2A (UniProtKB ID Q06190) has 
been reported to bind to the SHIP2 regulatory domain and prevent 
EGF-induced EGFR degradation, thus sustaining EGF-mediated 
signalling [89]. In serum-maintained cells SHIP2 has a perinuclear 
location: upon stimulation with EGF part of SHIP2 translocates to 
the plasma membrane of HeLa cells [90]. 
 
6. SHIP2 and the Immune System 
The FcγR proteins are low affinity receptors for immunoglobulin 
G (IgG) that function as modulators of immune responses [91]. 
They are membrane proteins in monocytes and macrophages 
that either, (a), have a partner adaptor protein to bring about an 
intracellular effect, or which, (b), contain, in an intracellular 
cytoplasmic tail, either an immunoreceptor tyrosine-based 
inhibition motif (ITIM) or the activation motif equivalent (ITAM). 
SHIP2 has been shown to interact with two types of FcγR, the 
ITAM-containing FcγRIIa (UniProtKB ID P12318) [30h], and the 
ITIM-containing FcγRIIb (UniProtKB ID P31994) [30d,e]. After the 
receptor binds its ligand the FcγRIIa ITAM becomes 
phosphorylated which allows other proteins to bind resulting in the 
activation of molecules involved in cell signalling leading to 
phagocytosis. In contrast to FcγRIIa with its ITAM is FcγRIIb 
which in place of the ITAM has an ITIM. 
 
One of the proteins shown to bind to the phosphorylated ITIM of 
FcγRIIb is SHIP2 [30d,e][92]. This followed earlier work 
demonstrating the binding of SHIP1 to FcγRIIb [30a]. It was initially 
thought that the ITIM of FcγRIIb was sufficient for SHIP2 binding 
[93]. However, later work showed that sixteen C-terminal residues 
(containing a tyrosine-based motif) are also necessary [94] as are 
the adaptor proteins Grap (UniProtKB ID Q13588) and Grb2 
(UniProtKB ID P62993) [95]. (As mentioned above Grb2 also plays 
a role in cell developmental processes.) SHIP2 inhibits the 
proliferative response that is the downstream biological 
consequence of FcγRIIb signalling [96]. SHIP2 binds to the 
phosphorylated FcγRIIb that is found in the brains of Alzheimer’s 
disease (AD) sufferers. In a mouse model of AD the 
pharmacological inhibition of SHIP2 has been shown to reduce 
the memory impairments observed in AD [97]: dysregulation of 
PtdIns(3,4)P2 metabolism disrupts the phosphorylation of the tau 
protein that is associated with memory impairments. 
 
Enteropathogenic Escherichia coli bind to cell membranes and 
insert the bacterial translocated intimin receptor (Tir) into the host 
plasma membrane. The C-terminal region of Tir has a sequence 
that is homologous to ITIMs. SHIP2 binds to Tir and controls F-
actin-pedestal formation by interacting with Shc and generating a 
PtdIns(3,4)P2-enriched lipid platform to which the cytoskeletal 
regulator lamellipodin is recruited [98]. 
 
SHIP2 has been shown to interact with the T-cell surface 
glycoprotein CD4 (UniProtKB ID P01730) [30r]. CD4 is a co-
receptor that helps the T-cell receptor communicate with an 
antigen-presenting cell. The consequences of the interaction of 
SHIP2 with CD4 are unknown. However, SHIP2 appears to be 
important in immune cell recognition and interaction as it also 
binds to vascular cell adhesion protein 1 (VCAM-1; UniProtKB ID 
P19320) [30s] which is involved in leukocyte-endothelial cell 
adhesion. 
 
Basophils are granulocytic cells involved in inflammatory 
reactions and the allergic response. Cellular sensitivity and 
histamine release have been weakly correlated with SHIP2 
expression in basophils [99]. In contrast to basophils, which are the 
rarest type of granulocyte, the neutrophils are the most common 
type of granulocyte. Neutrophils have phagocytic activity and are 
recruited to sites of injury or infection. PtdIns(3,4,5)P3 is 
necessary for neutrophil motility: by dephosphorylating 
PtdIns(3,4,5)P3 SHIP2 limits neutrophil activity [100]. 
 
Another type of phagocyte is the macrophage. When 
macrophages are stimulated with macrophage colony-stimulating 
factor (M-CSF; UniProtKB ID P09603) SHIP2 associates with the 
M-CSF receptor (UniProtKB ID P07333) at the cell membrane, 
becomes phosphorylated on a tyrosine residue, and associates 
with the actin-binding protein filamin in an interaction that requires 
the proline-rich domain but not the SH2 domain [101]. In response 
to M-CSF stimulation the activation of Akt/PKB by SHIP2 was 
reduced and NF-κB-mediated gene transcription was inhibited. 
 
SHIP2 is widely expressed, but SHIP1 is predominantly found in 
cells of haematopoietic origin. In murine platelets SHIP1 plays the 
major role in regulating the response to thrombin or collagen 
activation through controlling PtdIns(3,4,5)P3 levels [102]. 
 
Following antigen receptor stimulation phospholipase Cγ (PLCγ; 
UniProtKB IDs P19174, P16885) is activated in a process that 
involves the Tec tyrosine kinase (UniProtKB ID P42680). This 
process requires the activation of PI3K which stimulates the 
membrane localization of Tec. SHIP1 and SHIP2 interact with, 






and negatively regulate, Tec [103]. The interaction occurs through 
the Tec SH3 domain, removal of which generates a hyperactive 
form of Tec. 
 
SHIP2 has been shown to interact with discoidin domain receptor 
1 (UniProtKB ID Q08345) [30t], a tyrosine kinase that by 
upregulating matrix metalloproteinases, regulates remodelling of 
the extracellular matrix and wound healing. 
 
7. SHIP2 Modulators: Studies on the Isolated 
Enzyme 
This section discusses the discovery of SHIP2 modulators, their 
structures and any in vitro data that have been revealed. The 
consequences of the inhibition for cells and organisms are 
discussed in the next section. For comparative purposes data for 
SHIP1 modulators are briefly mentioned. Detailed studies of the 
SHIP2 reaction mechanism have not been carried out, though 
results from a study of type II inositol 1,4,5-trisphosphate 5-
phosphatase (INPP5B) have been used to identify some of the 
residues that might be involved [40]. 
 
The first mention of SHIP2 inhibitors in the literature came in 2006 
when a microfluidic assay for SHIP2 was described [104]. A library 
of 91,060 compounds was screened in this assay, with 1,343 
causing inhibition ≥70% (a 1.5% hit rate). Retesting of 1,116 of 
these compounds confirmed 721 (64%) as being SHIP2 inhibitors. 
With IC50 = 0.37µM inhibition data for only one of these 
compounds have been released: similar levels of inhibition by this 
compound were observed for SHIP1 and PTEN. The structure of 
none of the inhibitors has been revealed. 
 
Phosphorylated benzene and biphenyl polyols have been studied 
as potential inhibitors of inositol phosphatases because they have 
phosphate groups positioned around a planar six-membered ring 
with the phosphate regiochemistry similar to, but more rigid than 
that of the natural inositol phosphates, and it was thought that they 
would be able to bind to inositol phosphate binding proteins. Using 
inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) as the 
substrate three phosphorylated benzene derivatives (benzene 
1,2,4,5-tetrakisphosphate (Bz(1,2,4,5)P4, 1), benzene 1,2,3,4-
tetrakisphosphate (Bz(1,2,3,4)P4, 2) and benzene 1,2,3,5-
tetrakisphosphate (Bz(1,2,3,5)P4, 3)) were found to be inhibitors 
of the SHIP2 catalytic domain with IC50 values of 11.2µM, 19.6µM 
and 40.0µM, respectively [105]. However, in the same study, a 
phosphorylated biphenyl compound, biphenyl 2,3ʹ,4,5ʹ,6-
pentakisphosphate (BiPh(2,3ʹ,4,5ʹ,6)P5, 4), was found to be a 
more potent inhibitor of SHIP2 with IC50 = 1.8µM, though 
subsequent work has reported an IC50 value of 24.8µM under the 
same conditions [41]. The inhibitor was not dephosphorylated, i.e. 
it is not a SHIP2 substrate. It also inhibited type I inositol 1,4,5-
trisphosphate 5-phosphatase (UniProtKB ID Q14642), inhibited 
the binding of Ins(1,4,5)P3 to the type I inositol 1,4,5-trisphosphate 
receptor (UniProtKB ID Q14643), but did not inhibit Ins(1,4,5)P3 
3-kinase A (UniProtKB ID P23677) [105].  
 
 
BiPh(2,3ʹ,4,5ʹ,6)P5 (4) is the only ligand reported to have been 
crystallised with the catalytic domain of SHIP2 [41]. The crystal 
structure contains two SHIP2 catalytic domain monomers but only 
one molecule of BiPh(2,3ʹ,4,5ʹ,6)P5 which is bound in a shallow 
pocket. The ligand has several direct contacts with the protein and 
other hydrogen bonds to water molecules that, in turn, are 
hydrogen bonded to the protein, other water molecules, or 
another part of the ligand. The 2-phosphate moiety is engaged in 
three water-mediated hydrogen bonds, one to the 4-phosphate 
and the others to the surrounding solvent. The 4-phosphate has 
hydrogen bonds to both the sidechain and backbone of Asn566 
as well as to two water molecules. The 6-phosphate has hydrogen 
bonds to the sidechains of three residues: Arg611, Tyr661 and 
Arg682. It also forms a water-mediated hydrogen bond to the 
sidechain of Asn684 and forms another hydrogen bond to a water 
molecule. The 5ʹ-phosphate has hydrogen bonds to two solvent-
exposed water molecules and both it and the 3ʹ-phosphate form 
hydrogen bonds to both Lys541 and Ser564: the hydrogen bond 
from the 3ʹ-phosphate is to the backbone of Ser564. 
 
Several of the residues that interact with the ligand are in a loop 
that, in the crystal structure, contacts a symmetry related protein 
molecule. Removal of this symmetry related protein molecule 
followed by a molecular dynamics study of the loop suggest that 
it has the flexibility to close over the ligand and make additional 
interactions. Hence, the sidechain of Lys568 can form a π-π 
stacking interaction with one of the rings, and the sidechains of 
Lys541 and Lys677 can also make π-π stacking interactions, from 
opposite sides, with the other ring. Additional hydrogen bonds are 
formed between the protein and the ligand and some of the water-
mediated hydrogen bonds are lost [41]. The flexibility of this loop 
needs to be taken into consideration when designing ligands to 
inhibit SHIP2. 
 






Combinatorial libraries have been screened by a high throughput 
affinity selection-mass spectrometry technique [106]. Over three 
million compounds from 2,000 mixture-based combinatorial 
libraries were evaluated in the screen and 242 compounds were 
identified as being inhibitors. The structures of seventeen of these 
compounds, based on three different core structures, have been 
revealed with SHIP2 IC50 values ranging from 1.1µM to 50µM. Of 
the compounds revealed compound NGD-61338 (5, based on 
core structure 6) was one of the most potent with IC50 = 1.1µM. 
Competitive binding data suggest that NGD-61338 binds to the 
same site in SHIP2 as the substrate, phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3). Other core structures revealed 
were 7 and 8. One of the compounds based on core structure 7 
was shown to compete with NGD-61338 (5) for binding to SHIP2 
suggesting that compounds with this very different core structure 




High-throughput screening of a compound library resulted in the 
identification of AS1949490 (9) as a competitive inhibitor of SHIP2 
with IC50 = 0.62µM and Ki = 0.44µM when using Ins(1,3,4,5)P4 as 
the substrate [107]. Also identified was AS1938909 (10) with IC50 = 
0.57µM and Ki = 0.44µM [108]. Both were over twenty times more 
potent against SHIP2 than SHIP1 and failed to inhibit a number 
of other phosphatases suggesting they are selective for SHIP2. 
 
A ligand-based drug discovery programme used NGD-61338 (5) 
and AS1949490 (9) as templates for potential new 
pharmacophores [109]. This yielded four related core structures 
(11-14) but no enzyme inhibition data have been released for 
them. However, some in vivo data (discussed below) have been 
released for one of the compounds, CPDA (15). Patent WO 
2012/169571 [110] exemplifies thirty compounds with these core 
structures but also provides no inhibition data. In a more recent 
patent the same group has exemplified twenty compounds based 
on a (benzenesulfonylamino) benzamide core structure (16) but, 
again, no inhibition data are provided [111]. 
 
A high-throughput screen of a chemical library identified three 
compounds as being inhibitors of both SHIP1 and SHIP2 [59]. 
Compounds 1PIE (17), 6PTQ (18) and 2PIQ (also known as K103, 
19) inhibited SHIP2 with IC50 values of 30µM, 63µM and 500µM, 
respectively, and SHIP1 with IC50 values of 30µM, 35µM, 500µM, 
respectively. Another compound, K149 (20), at a concentration of 
500μM, reduces SHIP2 activity by about 40% and has been 
shown to have significant effects in colorectal cancer cells [62]. 
 
The high-throughput screen that led to the identification of 17, 18 
and 19 was originally designed to find inhibitors of SHIP1 [112]. This 
had identified 3-α-aminocholestane (3AC, 21) as a SHIP1 
inhibitor with IC50 = 10µM; it does not inhibit SHIP2. Some 
stabilized PtdIns(3,4,5)P3 analogues (22-26) have been tested 
against both SHIP1 and SHIP2 [113]. Compounds 22 and 23 were 
partially dephosphorylated by SHIP2 but no such hydrolysis of 24, 
25 or 26 was observed. Compounds 22, 23 and 26 were found to 
inhibit the SHIP1-catalysed hydrolysis of Ins(1,3,4,5)P4 but none 
of them inhibited SHIP2. 
 
 









As well as inhibitors of SHIP1 there are also several reports of 
SHIP1 activators. Pelorol (27), a natural product, and a number of 
synthesized analogues have been found to have in vivo effects 
consistent with activation of SHIP1 [114]. The in vitro effects of 
pelorol were reported alongside those of the more potent SHIP1 
activator, and pelorol analogue, AQX-016A (28) which also has in 
vivo effects consistent with SHIP1 activation: it is only a poor 
activator of SHIP2 [33]. The in vivo effects of the related compound 
AQX-MN100 (29) have also been reported but without any data 
pertaining to SHIP2 activity [115]. It has been suggested that these 
compounds allosterically activate SHIP1 by binding to the putative 
C2 domain [33]. A racemic pelerol analogue (30a and 30b) is as 
potent as AQX-MN100 in activating SHIP1 but has better 
pharmacological properties [116]. Pelorol derivatives with the core 
structure 31 have been the subject of a patent application [117] but 
little biological data are given. 
 
 
Another SHIP1 activator, AQX-1125 (32), is orally active, reduces 
the response to allergen challenge, and reduces airway 
inflammation in asthma [118]. Pharmacokinetic studies of AQX-
1125 in dogs and rats have been carried out and the tissue 
distribution in rats has been analysed [119]. At a concentration of 
300µM it increases SHIP1 activity by 20% and does so by 
decreasing KM and increasing kcat/KM [119]. Another compound, 
AQX-MN115 (33), under the same conditions increases SHIP1 
activity by 77% and does so by having similar effects on the 
kinetic parameters [119]. 
A natural product isolated from a Bacillus species, turnagainolide 
B (34), was shown to activate SHIP1 to the same extent as AQX-
MN100 [120]. A methanolic extract of a soft coral species was 
active in a SHIP1 assay and purification yielded four diterpenoids, 
one of which, australin E (35), was shown to activate SHIP1 [121]. 
 
With the exception of the limited data for AQX-016A none of these 
SHIP1 activators appears to have been evaluated against SHIP2. 
One SHIP2 activator has been found: anionic lipids in the form of 
vesicles of phosphatidylserine (36) are able to stimulate an 
increase of up to 9-fold in catalytic activity of both intact SHIP2 
and the isolated catalytic domain when using di-C8-
PtdIns(3,4,5)P3 as the substrate but not when using 













8. SHIP2 Modulators: Effects on Cells and 
Organisms 
The roles of SHIP2 in insulin signalling, apoptosis and immune 
system function have been described above. The in vivo 
consequences of SHIP2 inhibition have been studied with respect 
to the effects on either insulin signalling (compounds 9, 10 and 
15) or apoptosis (compounds 17, 18 and 19). No studies have 
looked at what effects, if any, SHIP2 inhibition may have on 
immune system function or bone ossification. 
 
The in vivo effects of BiPh(2,3ʹ,4,5ʹ,6)P5 (4) have been studied 
only in so far as they pertain to the modulation of Ca2+ responses 
in rat hepatocytes [105]. Since this is related to the inhibition of type 
1 inositol 1,4,5-trisphosphate 5-phosphatase and the inhibition of 
binding of Ins(1,4,5)P3 to the type 1 inositol 1,4,5-trisphosphate 
receptor rather than to the inhibition of SHIP2 the in vivo effects 
of this compound will not be discussed further. 
 
Compounds AS1949490 (9) and AS1938909 (10) cause a dose-
dependent increase in insulin-induced phosphorylation of 
Akt/PKB (UniProtKB ID P31749, P31751, Q9Y243) in L6 
myotubes [107][108]. This phosphorylation activates Akt/PKB leading 
to an increase in glucose uptake and metabolism in L6 myotubes, 
this increased uptake being associated with greater expression of 
GLUT1 mRNA and more GLUT1 protein (UniProtKB ID P11166). 
In cultured hepatocyte FAO cells AS1949490 decreased insulin-
induced gluconeogenesis. When given to normal mice 
AS1949490 was found to do this by suppressing the expression 
of proteins involved in gluconeogenesis: the levels of mRNA 
coding for PEPCK (UniProtKB ID P35558, Q16822) and G6Pase 
(UniProtKB ID P35575, Q9NQR9, Q9BUM1) were reduced by 
approximately 50%. In diabetic db/db mice the twice daily oral 
administration of AS1949490 significantly reduced plasma 
glucose levels with no effect on food intake, body weight or insulin 
levels, and in an oral glucose tolerance test significantly reduced 
both fasting blood glucose and the area under the blood glucose 
concentration time curve. These antidiabetic effects were found 
to be a consequence of an enhancement of insulin signalling: the 
phosphorylation and, hence, activity of GSK3β (UniProtKB ID 
P49841) was increased without changing the amount of GSK3β. 
 
Compound CPDA (15) has also been investigated for its effects 
on insulin signalling [122]. In 3T3-L1 adipocytes CPDA antagonizes 
the attenuation of the insulin-induced phosphorylation of Akt2 
(UniProtKB ID P31751) caused by tumour necrosis factor α 
(TNFα, UniProtKB ID P01375), and does so more potently than 
AS1949490. This greater potency of CPDA in stimulating the 
phosphorylation of Akt was observed, also, in primary cultured 
neuronal cells from the rat cerebral cortex. In C57BL/6J mice the 
twice daily oral administration of 300mg/kg had no effect on 
fasting blood glucose levels, and normal glucose tolerance was 
observed in a glucose tolerance test. However, in db/db mice 
fasting blood glucose levels fell significantly and, during the 
glucose tolerance test, CPDA significantly reduced the rise in 
blood glucose levels compared to controls. As with AS1949490 
the amounts of PEPCK and G6Pase were significantly reduced in 
CPDA-treated mice. 
 
Compounds 1PIE (17), 6PTQ (18) and 2PIQ (19) inhibit both 
SHIP1 and SHIP2 [59]. In three multiple myeloma cell lines 
(RPMI8226, OPM2 and U266) all three inhibitors at a 
concentration of 7.5µM caused statistically significant levels of 
cell death with some variation between inhibitor and cell line. The 
more selective SHIP1 inhibitor 3AC (21) was less effective in 
killing the cells. Treatment of the multiple myeloma cells with 
10µM 1PIE (16) found that the cells went into cell cycle arrest at 
the G2/M phase with an increase in the number of cells in the sub-
G0/G1 phase and activation of the intrinsic apoptotic pathways. 
The viability of two breast cancer cell lines (MDA-MB-231 and 
MCF-7) was severely reduced by treating them with 1PIE (17), 
6PTQ (18) or 2PIQ (19). This is significant because these cell 
lines do not express SHIP1, so the cell-killing effects of these 
compounds are probably due to SHIP2 inhibition. This is 
supported by the finding that the addition of PtdIns(3,4)P2 (the 
product of the SHIP2-catalysed reaction) to MCF-7 cells treated 
with these inhibitors rescued the cells while having little effect on 
cells that had not been treated with the inhibitor. 
 
The finding that SHIP2 activity is stimulated in the presence of 
phosphatidylserine vesicles [5a] suggests that interaction with 
membranes may stimulate SHIP2 activity. However, since the 
SHIP2 substrate is found embedded in membranes it is possible 
that this enhanced activity is actually the default level of activity in 
vivo because the enzyme will necessarily be interacting with, or 
at least be in very close proximity to, the membrane. 
Phosphatidylserine is normally held facing the cytosolic side of 
the cell membrane. During apoptosis it flips to face the cell 
exterior where it acts as a signal for macrophages to engulf cells 
[123]. It is possible that this is of significance because, as discussed 
above, SHIP2 is known to play a role in apoptosis both through 
its interactions with a number of proteins involved in the apoptotic 
process, and because inhibition of SHIP2 by 17, 18 and 19 
causes apoptosis [59]. Furthermore, if SHIP2 does interact with 
phosphatidylserine in vivo then it has to dissociate before the 
phosphatidylserine can flip to face the cell exterior. 
 
 






9. Summary and Outlook 
In the sections above what is known about the structure of SHIP2 
has been discussed, as have the interactions a number of 
proteins can make with the various SHIP2 domains and motifs. It 
should be stressed that several of these interactions have been 
observed only under the conditions of in vitro experiments and 
there might be, as yet, little or no evidence that these interactions 
occur in vivo. 
 
The interactions have been discussed on the basis of the role of 
the proteins, i.e. some are involved in cytoskeletal function and 
apoptosis, and others in immune system function: others, not 
discussed, might be involved in insulin signalling. It should be 
noted that some of the proteins with which SHIP2 has been 
reported to interact have a role in more than one of these areas. 
All the studies of SHIP2 interactions with other proteins have been 
performed with isoform 1 of the protein, i.e. the full-length protein. 
There is little information about the interactions made by isoform 
2 which lacks the N-terminal 242 residues of isoform 1 and, hence, 
the SH2 domain. It is not known if the expression of isoform 2 is 
temporally or spatially regulated, or what proportion of the SHIP2 
in a cell is isoform 2. 
 
The in vitro and in vivo modulation of SHIP2 activity by inhibitors 
and activators are then discussed. The known inhibitors of SHIP2 
have been assayed either for their ability to interfere with insulin 
signalling or to induce apoptosis, but none of them for both. (The 
role of SHIP2 inhibitors in the modulation of immune system 
function or bone ossification has not been studied.) The specificity 
and selectivity of most of the inhibitors have not been determined 
to any real extent, and most have IC50 values in the low-to-mid 
micromolar range so, for at least some of them, may not be potent 
enough for medicinal use: any progress towards medicinal use 
has not been revealed. 
 
Several activators of SHIP1 are known and it is disappointing that 
there is SHIP2 activation data for only one of these compounds 
(AQX-16A, 28) [33]. The increase in SHIP2 activity in the presence 
of phosphatidylserine vesicles raises the possibility that this 
greater level of activity could be the basal level of activity in cells. 
It is not known how phosphatidylserine interacts with SHIP2, but 
it is reasonable to suppose that it is not in the substrate binding 
site. PTEN is stimulated by phosphatidylserine which induces a 
conformational change in the protein structure [124] suggesting that 
allosteric activation of SHIP2 is a possibility. It is not known 
whether, or to what extent, SHIP2 inhibitors will inhibit 
phosphatidylserine-activated SHIP2. If SHIP2 is allosterically 
activated by phosphatidylserine and the activation changes the 
size or shape of the substrate binding site then compounds that 
inhibit the non-activated form of the enzyme may not inhibit the 
activated form (and vice versa) or have a different level of 
inhibitory activity. 
 
The ligand-binding domain has a flexible loop that can close over 
the substrate binding site [41], though the crystal structure of the 
apo-enzyme has the same open structure as the structure with a 
ligand in the substrate binding site. When the loop is closed it 
makes more interactions with the ligand and expels some waters 
from the binding site. This greatly complicates the use of the 
protein structure in structure-based drug discovery programs: to 
what extent should the loop be closed over the binding site when 
embarking on a virtual screening program? Depending on the size 
of the ligand the loop will be able to close over it to different 
extents. 
 
Many small molecule, peptidic and peptidomimetic inhibitors of 
SH2 domains have been described [42][125] though none appears 
to have been tested for its effects on SHIP2. The effects of a 
SHIP2 SH2 inhibitor are hard to predict because of the current 
lack of knowledge of the function of isoform 2 of SHIP2. 
 
It is over twenty years since SHIP2 was discovered. In that time 
much has been learnt about the role of SHIP2, but there are still 
many gaps in our knowledge. Do all the proteins shown by in vitro 
experiments to interact with SHIP2 do so in vivo and, if so, with 
what effect on cellular function? What are the (presumably 
differing) roles of the two SHIP2 isoforms? Will roles for SHIP2 be 
confirmed in areas other than bone ossification and 
opsismodysplasia? What role does SHIP2 over- or under-
expression play in disease development? What role, if any, will 
SHIP2 inhibitors play in the treatment of disease? Can more 
potent and/or selective SHIP2 inhibitors be developed? These, 
and other questions, will, hopefully, be answered in the next few 
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The SHIP2 phosphatase catalyses 
dephosphorylation at the 5-position 
of phosphoinositides, mediating 
diverse biological effects, but much 
still remains unknown. Inhibitors 
come from a range of structural 
classes, but still merit further 
development. This review brings 
together interdisciplinary facets of 
SHIP2 progress and discusses 
possible future directions. 
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